Literature DB >> 12551731

Alpha-synuclein, Abeta and Alzheimer's disease.

Oliver Wirths1, Thomas A Bayer.   

Abstract

Alpha-synuclein is a presynaptic protein that is implicated in the pathogenesis of various neurodegenerative diseases. Missense mutations in the alpha-synuclein gene are linked to familial cases of Parkinson's disease (PD), and it has further been shown that alpha-synuclein is a major constituent of the Lewy bodies in sporadic PD and dementia with Lewy body (DLB). The contribution of alpha-synuclein to the pathological changes in Alzheimer's disease (AD) has been currently a matter of scientific debate. Some reports hypothesized that alpha-synuclein may play a role in amyloid beta/A4 protein (Abeta) aggregation in senile plaques, whereas recent reports challenged this finding by showing a lack of alpha-synuclein-immunoreactivity in Abeta plaques. In this review, we report on recent findings on the physiological and pathological role of alpha-synuclein and try to elucidate its possible contribution to AD pathology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12551731     DOI: 10.1016/S0278-5846(02)00339-1

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  15 in total

1.  Prominent neuroleptic sensitivity in a case of early-onset Alzheimer disease due to presenilin-1 G206A mutation.

Authors:  Steven P Cercy; Martin J Sadowski; Thomas Wisniewski
Journal:  Cogn Behav Neurol       Date:  2008-09       Impact factor: 1.600

2.  Coordination features and affinity of the Cu²+ site in the α-synuclein protein of Parkinson's disease.

Authors:  Christopher G Dudzik; Eric D Walter; Glenn L Millhauser
Journal:  Biochemistry       Date:  2011-02-14       Impact factor: 3.162

Review 3.  A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment.

Authors:  Brati Das; Riqiang Yan
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

4.  Interactions between Soluble Species of β-Amyloid and α-Synuclein Promote Oligomerization while Inhibiting Fibrillization.

Authors:  Jason Candreva; Edward Chau; Margaret E Rice; Jin Ryoun Kim
Journal:  Biochemistry       Date:  2019-12-30       Impact factor: 3.162

5.  Cystatin C prevents neuronal loss and behavioral deficits via the endosomal pathway in a mouse model of down syndrome.

Authors:  Gurjinder Kaur; Sebastien A Gauthier; Rocio Perez-Gonzalez; Monika Pawlik; Amol Bikram Singh; Benjamin Cosby; Panaiyur S Mohan; John F Smiley; Efrat Levy
Journal:  Neurobiol Dis       Date:  2018-09-01       Impact factor: 5.996

6.  p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy.

Authors:  Yun Ju C Song; Ditte M S Lundvig; Yue Huang; Wei Ping Gai; Peter C Blumbergs; Peter Højrup; Daniel Otzen; Glenda M Halliday; Poul H Jensen
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

7.  Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.

Authors:  Stephanie M Williams; Philip Schulz; Michael R Sierks
Journal:  Eur J Neurosci       Date:  2015-10-15       Impact factor: 3.386

Review 8.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

9.  Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo.

Authors:  John W Steele; Soong H Kim; John R Cirrito; Deborah K Verges; Jessica L Restivo; David Westaway; Paul Fraser; Peter St George Hyslop; Mary Sano; Ilya Bezprozvanny; Michelle E Ehrlich; David M Holtzman; Sam Gandy
Journal:  Mol Neurodegener       Date:  2009-12-17       Impact factor: 14.195

10.  Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain.

Authors:  J W Steele; S Ju; M L Lachenmayer; J Liken; A Stock; S H Kim; L M Delgado; I E Alfaro; S Bernales; G Verdile; P Bharadwaj; V Gupta; R Barr; A Friss; G Dolios; R Wang; D Ringe; A A Protter; R N Martins; M E Ehrlich; Z Yue; G A Petsko; S Gandy
Journal:  Mol Psychiatry       Date:  2012-08-07       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.